266 F. Supp. 3d 750
E.D. Pa.2017Background
- Plaintiffs (direct purchasers of traditional blood reagents, "TBRs") allege Ortho and Immucor conspired to fix TBR prices from 2000–2009, producing large increases (some products rose dramatically) after the market consolidated into a duopoly by 1999.
- Ortho led major price initiatives in 2000–2001 (shift from a planned modest program to the large Blood Bank Leadership Plan), again in 2005, and in 2008; Immucor followed with parallel or tiered increases and cancelled GPO contracts in 2004 to implement higher prices.
- Key alleged conspiracy evidence for 2001: (1) abrupt change in Ortho’s pricing plan, (2) pricing-related communications at the November 2000 AABB meeting between senior Ortho and Immucor personnel, and (3) a direct transfer of Ortho price lists to Immucor shortly before the 2001 increase.
- For 2005 and 2008 plaintiffs rely on parallel increases, opportunity to communicate, GPO contract cancellations, internal communications, and expert economic analysis (Dr. Beyer) arguing costs/demand do not explain the magnitude of increases; defendants counter with alternative economic analyses and lawful explanations.
- Procedural posture: MDL consolidating 33 cases; Immucor settled (2012); Ortho moved for summary judgment; court applies per se price-fixing standard and Matsushita framework for summary judgment review.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether per se price-fixing standard applies | Plaintiffs maintain they allege an ongoing horizontal price-fixing conspiracy, so per se applies | Ortho contends plaintiffs abandoned a price-fixing theory and exchange-of-information/rule-of-reason should govern | Court: Per se standard applies — plaintiffs did not abandon conspiracy allegations |
| Whether pricing in 2001, 2005, 2008 was parallel and actionable | Plaintiffs: pricing was parallel and supported by plus factors (motive, actions contrary to interest, traditional-conspiracy evidence) | Ortho: 2005/2008 pricing not parallel; statistical and business explanations show interdependence, not conspiracy | Court: Genuine dispute on 2001 parallelism; 2005 and 2008 raise genuine issues of parallel conduct but not sufficient traditional-conspiracy evidence to survive summary judgment |
| Whether non‑economic (traditional) evidence tends to exclude independent conduct | Plaintiffs point to direct executive communications, lunch where Ortho prices were shown to Immucor, and risky GPO cancellations as evidence of express conspiracy | Ortho argues meetings/opportunities and internal comments reflect lawful oligopolistic behavior and business judgment, not an agreement | Court: Traditional-conspiracy evidence suffices for 2001 (communications + price-list transfer + abrupt shift); insufficient for 2005 and 2008 (evidence consistent with lawful interdependence) |
| Whether statute of limitations bars claims before May 18, 2005 (fraudulent concealment) | Plaintiffs: DOJ investigation announcement (May 2009) was triggering event; plaintiffs lacked access to internal communications and exercised reasonable diligence, so equitable tolling applies | Ortho: Plaintiffs knew or should have known earlier (public posts, market facts) and lacked diligence | Held: Genuine factual disputes on awareness and diligence — summary judgment on tolling denied (claims before May 18, 2005 survive for trial) |
Key Cases Cited
- Matsushita Elec. Indus. Co. v. Zenith Radio Corp., 475 U.S. 574 (Matsushita) (summary‑judgment standard in §1 cases; plaintiff must exclude independent-action inference)
- Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (Twombly) (parallel conduct alone insufficient; pleads must show agreement)
- United States v. Socony‑Vacuum Oil Co., 310 U.S. 150 (Socony‑Vacuum) (horizontal price‑fixing treated as per se illegal)
- Brooke Group Ltd. v. Brown & Williamson Tobacco Corp., 509 U.S. 209 (Brooke Group) (outline of tacit collusion concept and relevant economic analysis)
- In re Chocolate Confectionary Antitrust Litig., 801 F.3d 383 (3d Cir.) (discusses plus factors and evidence needed to distinguish interdependence from conspiracy)
- In re Flat Glass Antitrust Litig., 385 F.3d 350 (3d Cir.) (price discussions among high‑level executives and effect on pricing decisions probative of conspiracy)
- In re Baby Food Antitrust Litig., 166 F.3d 112 (3d Cir.) (possession/exchange of competitive memoranda by low‑level employees insufficient to show conspiracy)
- InterVest, Inc. v. Bloomberg, L.P., 340 F.3d 144 (3d Cir.) (Matsushita standard applies absent direct evidence of conspiracy)
- Monsanto Co. v. Spray‑Rite Serv. Corp., 465 U.S. 752 (Monsanto) (conduct as consistent with competition and conspiracy does not alone support inference of illegal agreement)
- In re Blood Reagents Antitrust Litig., 756 F. Supp. 2d 623 (E.D. Pa.) (earlier MDL ruling denying motions to dismiss; part of the procedural history)